title: [What's New in Dermatological Therapy?].
abstract: During the ongoing year were published results from clinical trials opening new perspectives in the treatment of chronic inflammatory and dysimmune skin diseases. If this therapeutic development still predominantly on moderate-to- severe forms of plaque psoriasis, it tends to be more diversified towards moderate-to- severe forms of other diseases heavily impacting on patients'lives such as atopic dermatitis in adulthood, and hidradenitis suppurativa. Likewise, the development of IL-17 and IL-23 biological inhibitors, but also of small molecules such as tofacitinib in psoriasis, and the achievement of dupilumab phase 2 studies in atopic dermatitis provide evidence for the high efficacy of these therapies, while adalimumab is the first drug to be approved for the treatment of hidradenitis suppurativa. On the other hand, advances in vaccinology allowed the successful development of innovative vaccine respectively against Herpes zoster and 9 serotypes of human papillomavirus. For all these interventions, prolonged real-life pharmacovigilance will be necessary to provide a more accurate picture of their respective benefit-to- risk balances.
authors.affiliation: Service de dermatologie, AP-HP, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75475 Paris Cedex 10 ; Sorbonne Paris Cité - Université Paris-Diderot, Paris ; Groupe de recherche sur les pathologies auto-inflammatoires, INSERM U1163, institut Imagine, Paris, France. Electronic address: herve.bachelez@aphp.fr.
authors.forename: H
authors.initials: H
authors.lastname: Bachelez
mesh_terms: D003876:Dermatitis, Atopic / Q000188:drug therapy*; D017497:Hidradenitis Suppurativa / Q000188:drug therapy*; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy*
keywords: Atopic dermatitis; Dermatite atopique; Hidradenitis suppurativa; Hidradénite suppurée; Human papillomavirus vaccine; Psoriasis; Vaccin antipapillomavirus humain; Vaccin antizona; Zoster vaccine